Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript

Chemomab Therapeutics and Scipher Medicine held a merger announcement conference call on July 8, 2026, describing a proposed merger along with concurrent financing and expected post-merger ownership/leadership changes. The companies also reiterated plans for the clinical development of Nebokitug for rheumatoid arthritis, which is central to the combined pipeline narrative.

Analysis

This looks more like a capital-structure event than a clean operating rerate. In microcap biotech, the first move is usually driven by the promise of a larger financing base and a longer runway, but the second move is dictated by who is actually issuing equity and how much legacy holder dilution is embedded. If the combined company uses CMMB as the public currency for a private asset, the economic winner is often the target’s existing owners and bankers, while legacy public holders absorb the dilution and the execution risk.

The key competitive implication is that the merged entity is now trying to buy time in one of the most crowded corners of healthcare capital allocation: immunology/RA. That means the stock will trade less on strategic rhetoric and more on whether management can show a credible path to differentiated clinical data before the market turns skeptical on the financing overhang. In the next 1-3 months, any rally is likely to depend on deal terms, ownership split, and runway; in 6-18 months, the only durable upside comes from evidence that the asset can compete against entrenched TNF/JAK/IL-6 standards without forcing repeated raises.

The contrarian risk is that investors may be overestimating the value of "extended runway" while underestimating the cost of buying that runway. If the financing is equity-heavy, the deal can function as a temporary relief rally followed by chronic supply overhang, especially in a name with limited institutional sponsorship. The thesis is falsified if the post-close cap structure is genuinely clean — e.g., meaningfully reduced burn, little dilution, and a disclosed clinical timeline that can survive 12+ months without another raise.

Key Decisions for Investors

• Do not chase CMMB on the headline alone; wait for merger consideration and financing terms. If the stock rallies sharply on release and the financing is materially dilutive, fade the move over the next 1-3 months via short CMMB or a relative short against XBI, with a stop if the implied post-money valuation holds above the pre-deal market cap.
• Treat this as an alert, not a conviction long, until the pro forma cash runway is disclosed. Only consider a long if management shows >12-18 months of runway with less than ~25% dilution; otherwise the risk/reward skews negative because each additional quarter of life is being purchased by existing holders.
• If borrow is available and liquidity supports it, use CMMB as a short-event-overhang name into any post-announcement strength. Base case is mean reversion after the initial M&A pop as the market digests supply, lockups, and execution risk; target horizon 4-12 weeks, invalidated by a clean close with unusually favorable financing.
• Watch for a catalyst stack: merger close, financing pricing, and any first disclosure on trial timetable. A better entry for longs would be after the financing clears and the stock has digested the new float; until then, the trade is the overhang, not the science.
• If the sector basket is needed instead of idiosyncratic shorting, pair long IBB/XBI against short CMMB only as a tactical relative-value expression. This isolates deal-specific dilution risk while keeping market beta neutral, but it is only attractive if the borrow is efficient and the stock remains liquid enough.